On October 9, 10x Genomics, Inc. rose 6.25% in regular trading to $82.04 per share, with turnover of $24.10 million. The rally followed BofA Securities' decision to raise its price target on the company from $50 to $80, a move that significantly lifted market sentiment.

The upward revision stands out against the consensus mean target of $58.80, indicating a notably more bullish view from BofA compared to the broader analyst community. The upgrade came one day after the company announced a multi-project research collaboration with Fred Hutchinson Cancer Center, though that earlier news had failed to provide support and was instead followed by a decline.

10x Genomics, Inc. focuses on life science technology, developing innovative instruments, consumables, and software for single-cell and spatial analysis. Its platforms support applications such as gene expression profiling, immune profiling, epigenetics, and spatial transcriptomics for academic, biopharmaceutical, and clinical research institutions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)